NASDAQ:TNFA - Nasdaq - US62856X2018 - Common Stock - Currency: USD
0.1294
+0.04 (+47.89%)
The current stock price of TNFA is 0.1294 USD. In the past month the price decreased by -7.24%. In the past year, price decreased by -93.26%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 55.39 | 722.35B | ||
JNJ | JOHNSON & JOHNSON | 16.44 | 395.46B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 17.69 | 288.46B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 12.9 | 220.96B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 15.8 | 213.06B | ||
MRK | MERCK & CO. INC. | 10.18 | 199.15B | ||
PFE | PFIZER INC | 7.56 | 137.93B | ||
SNY | SANOFI-ADR | 10.56 | 116.71B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.36 | 95.02B | ||
GSK | GSK PLC-SPON ADR | 8.15 | 73.23B | ||
ZTS | ZOETIS INC | 24.48 | 65.61B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.78 | 45.11B |
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. Isomyosamine works by regulating the release of numerous pro-inflammatory cytokines. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not regulated as drugs.
TNF PHARMACEUTICALS INC
1185 Avenue Of The Americas, Suite 249
New York City NEW YORK US
Employees: 2
Phone: 18568488698
The current stock price of TNFA is 0.1294 USD. The price increased by 47.89% in the last trading session.
The exchange symbol of TNF PHARMACEUTICALS INC is TNFA and it is listed on the Nasdaq exchange.
TNFA stock is listed on the Nasdaq exchange.
TNF PHARMACEUTICALS INC (TNFA) has a market capitalization of 1.83M USD. This makes TNFA a Nano Cap stock.
TNF PHARMACEUTICALS INC (TNFA) currently has 2 employees.
TNF PHARMACEUTICALS INC (TNFA) has a support level at 0.12. Check the full technical report for a detailed analysis of TNFA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TNFA does not pay a dividend.
TNF PHARMACEUTICALS INC (TNFA) will report earnings on 2025-08-18.
The outstanding short interest for TNF PHARMACEUTICALS INC (TNFA) is 27.62% of its float. Check the ownership tab for more information on the TNFA short interest.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to TNFA. The Buy consensus is the average rating of analysts ratings from 7 analysts.